Companies are pouring resources into anything that might become the next semaglutide. The combination of licensing deals, strategic partnerships, and IPOs underscores that investment in new obesity drugs is red-hot across the industry
Follow-up showed no developmental concerns
This takes us to the current body of clinical evidence investigating this experimental drug candidate
GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state via GSK-3beta pathway
Protein sources: Chicken, fish, lean beef, Greek yogurt, eggs, cottage cheese, protein powder (whey or high-quality plant blend)
Unlike every other GLP-1 receptor agonist on the market, including semaglutide and tirzepatide , orforglipron is not a peptide